• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

人巨细胞病毒糖蛋白gp55上线性抗原位点的分布

Distribution of linear antigenic sites on glycoprotein gp55 of human cytomegalovirus.

作者信息

Kniess N, Mach M, Fay J, Britt W J

机构信息

Institut für Klinische und Molekulare Virologie, Universität Erlangen-Nürnberg, Federal Republic of Germany.

出版信息

J Virol. 1991 Jan;65(1):138-46. doi: 10.1128/JVI.65.1.138-146.1991.

DOI:10.1128/JVI.65.1.138-146.1991
PMID:1702157
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC240498/
Abstract

Human convalescent serum and bacterial fusion proteins constructed from overlapping open reading frames of the nucleotide sequence encoding the human cytomegalovirus gp55 component of the major envelope glycoprotein complex, gp55-116 (gB), were used to localize antigenic regions recognized by human antibodies. All donor serum analyzed contained antibody reactivity for an antigenic site(s) located between amino acids (AA) 589 and 645, a region containing a previously defined linear site recognized by neutralizing monoclonal antibodies (U. Utz, B. Britt, L. Vugler, and M. Mach, J. Virol. 63:1995-2001, 1989). Furthermore, in-frame insertion of two different synthetic oligonucleotides encoding four amino acids into the sequence at nucleotide 1847 (AA 616) eliminated antibody recognition of the fusion protein. A second antibody binding site was located within the carboxyl terminus of the protein (AA 703 through 906). A competitive binding inhibition assay in which monoclonal antibodies were used to inhibit human antibody reactivity with recombinant gp55-116 (gB) suggested that the majority of human anti-gp55-116 (gB) antibodies were directed against a single antigenic region located between AA 589 and 645. Furthermore, inoculation of mice with fusion proteins containing this antigenic site led to a boostable antibody response. These results indicated that the antigenic site(s) located between AA 589 and 645 was an immunodominant antibody recognition site on gp55 and likely the whole gp55-116 (gB) molecule. The enhanced immunogenicity of this region in vivo may account for its immunodominance.

摘要

人恢复期血清以及由编码人巨细胞病毒主要包膜糖蛋白复合物gp55成分(gp55-116,即gB)的核苷酸序列的重叠开放阅读框构建的细菌融合蛋白,被用于定位人抗体识别的抗原区域。分析的所有供体血清都对位于氨基酸(AA)589至645之间的一个抗原位点具有抗体反应性,该区域包含一个先前定义的可被中和性单克隆抗体识别的线性位点(U. Utz、B. Britt、L. Vugler和M. Mach,《病毒学杂志》63:1995 - 2001,1989年)。此外,在核苷酸1847(AA 616)处将编码四个氨基酸的两种不同合成寡核苷酸读框内插入该序列,消除了融合蛋白的抗体识别。第二个抗体结合位点位于该蛋白的羧基末端(AA 703至906)。一项竞争性结合抑制试验,其中使用单克隆抗体抑制人抗体与重组gp55-116(gB)的反应性,表明大多数人抗gp55-116(gB)抗体针对位于AA 589和645之间的单个抗原区域。此外,用含有该抗原位点的融合蛋白接种小鼠会引发可增强的抗体反应。这些结果表明,位于AA 589和645之间的抗原位点是gp55上的一个免疫显性抗体识别位点,可能也是整个gp55-116(gB)分子的免疫显性抗体识别位点。该区域在体内增强的免疫原性可能解释了其免疫显性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a5a9/240498/d8d036ecf25e/jvirol00044-0163-c.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a5a9/240498/a694f01736e1/jvirol00044-0162-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a5a9/240498/78434125b78d/jvirol00044-0163-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a5a9/240498/c35c4644863d/jvirol00044-0163-b.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a5a9/240498/d8d036ecf25e/jvirol00044-0163-c.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a5a9/240498/a694f01736e1/jvirol00044-0162-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a5a9/240498/78434125b78d/jvirol00044-0163-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a5a9/240498/c35c4644863d/jvirol00044-0163-b.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a5a9/240498/d8d036ecf25e/jvirol00044-0163-c.jpg

相似文献

1
Distribution of linear antigenic sites on glycoprotein gp55 of human cytomegalovirus.人巨细胞病毒糖蛋白gp55上线性抗原位点的分布
J Virol. 1991 Jan;65(1):138-46. doi: 10.1128/JVI.65.1.138-146.1991.
2
Human cytomegalovirus strain Towne glycoprotein B is processed by proteolytic cleavage.人巨细胞病毒汤氏株糖蛋白B通过蛋白水解切割进行加工。
Virology. 1988 Nov;167(1):207-25. doi: 10.1016/0042-6822(88)90071-2.
3
Antibodies specific for the antigenic domain 1 of glycoprotein B (gpUL55) of human cytomegalovirus bind to different substructures.针对人巨细胞病毒糖蛋白B(gpUL55)抗原结构域1的特异性抗体与不同的亚结构结合。
Virology. 1996 Feb 1;216(1):133-45. doi: 10.1006/viro.1996.0040.
4
Humoral immune response to functional regions of human cytomegalovirus glycoprotein B.针对人巨细胞病毒糖蛋白B功能区的体液免疫反应。
J Med Virol. 1997 Aug;52(4):451-9.
5
Induction of complement-dependent and -independent neutralizing antibodies by recombinant-derived human cytomegalovirus gp55-116 (gB).重组人巨细胞病毒gp55 - 116(gB)诱导补体依赖性和非依赖性中和抗体
J Virol. 1988 Sep;62(9):3309-18. doi: 10.1128/JVI.62.9.3309-3318.1988.
6
Cell surface expression of human cytomegalovirus (HCMV) gp55-116 (gB): use of HCMV-recombinant vaccinia virus-infected cells in analysis of the human neutralizing antibody response.人巨细胞病毒(HCMV)gp55 - 116(gB)的细胞表面表达:在分析人中和抗体反应中使用HCMV重组痘苗病毒感染的细胞
J Virol. 1990 Mar;64(3):1079-85. doi: 10.1128/JVI.64.3.1079-1085.1990.
7
Construction of polyepitope fusion antigens of human cytomegalovirus ppUL32: reactivity with human antibodies.人巨细胞病毒ppUL32多表位融合抗原的构建:与人抗体的反应性
J Clin Microbiol. 1994 Feb;32(2):358-63. doi: 10.1128/jcm.32.2.358-363.1994.
8
The dominant linear neutralizing antibody-binding site of glycoprotein gp86 of human cytomegalovirus is strain specific.人巨细胞病毒糖蛋白gp86的主要线性中和抗体结合位点具有毒株特异性。
J Virol. 1992 Mar;66(3):1303-11. doi: 10.1128/JVI.66.3.1303-1311.1992.
9
Antigenic domain 1 of human cytomegalovirus glycoprotein B induces a multitude of different antibodies which, when combined, results in incomplete virus neutralization.人巨细胞病毒糖蛋白B的抗原结构域1可诱导产生多种不同抗体,这些抗体联合作用时会导致病毒中和不完全。
J Gen Virol. 1999 Aug;80 ( Pt 8):2183-2191. doi: 10.1099/0022-1317-80-8-2183.
10
Genetic analysis of type-specific antigenic determinants of herpes simplex virus glycoprotein C.单纯疱疹病毒糖蛋白C型特异性抗原决定簇的遗传分析
J Virol. 1992 Aug;66(8):4864-73. doi: 10.1128/JVI.66.8.4864-4873.1992.

引用本文的文献

1
Developing a Vaccine Against Human Cytomegalovirus: Identifying and Targeting HCMV's Immunological Achilles' Heel.开发针对人类巨细胞病毒的疫苗:识别并靶向人巨细胞病毒的免疫弱点。
Vaccines (Basel). 2025 Apr 22;13(5):435. doi: 10.3390/vaccines13050435.
2
The Autonomous Fusion Activity of Human Cytomegalovirus Glycoprotein B Is Regulated by Its Carboxy-Terminal Domain.人巨细胞病毒糖蛋白 B 的自主融合活性受其羧基末端结构域调控。
Viruses. 2024 Sep 18;16(9):1482. doi: 10.3390/v16091482.
3
Structure-based design of a soluble human cytomegalovirus glycoprotein B antigen stabilized in a prefusion-like conformation.

本文引用的文献

1
Protection against foot-and-mouth disease by immunization with a chemically synthesized peptide predicted from the viral nucleotide sequence.通过用根据病毒核苷酸序列预测的化学合成肽进行免疫接种来预防口蹄疫。
Nature. 1982 Jul 1;298(5869):30-3. doi: 10.1038/298030a0.
2
Analysis of adenovirus transforming proteins from early regions 1A and 1B with antisera to inducible fusion antigens produced in Escherichia coli.用针对在大肠杆菌中产生的可诱导融合抗原的抗血清分析来自早期区域1A和1B的腺病毒转化蛋白。
J Virol. 1984 Jan;49(1):132-41. doi: 10.1128/JVI.49.1.132-141.1984.
3
Neutralizing antibodies detect a disulfide-linked glycoprotein complex within the envelope of human cytomegalovirus.
基于结构的可溶性人巨细胞病毒糖蛋白 B 抗原的设计,该抗原稳定在预融合样构象中。
Proc Natl Acad Sci U S A. 2024 Sep 10;121(37):e2404250121. doi: 10.1073/pnas.2404250121. Epub 2024 Sep 4.
4
Assessing immune factors in maternal milk and paired infant plasma antibody binding to human rhinoviruses.评估母乳中的免疫因子和配对婴儿血浆抗体与人鼻病毒的结合。
Front Immunol. 2024 Jul 25;15:1385121. doi: 10.3389/fimmu.2024.1385121. eCollection 2024.
5
Multivalent cytomegalovirus glycoprotein B nucleoside modified mRNA vaccines did not demonstrate a greater antibody breadth.多价巨细胞病毒糖蛋白B核苷修饰mRNA疫苗并未显示出更广泛的抗体谱。
NPJ Vaccines. 2024 Feb 20;9(1):38. doi: 10.1038/s41541-024-00821-3.
6
A fully human neutralizing monoclonal antibody targeting a highly conserved epitope of the human cytomegalovirus glycoprotein B.一种针对人巨细胞病毒糖蛋白 B 高度保守表位的完全人源中和性单克隆抗体。
PLoS One. 2023 May 16;18(5):e0285672. doi: 10.1371/journal.pone.0285672. eCollection 2023.
7
Heterosubtypic, cross-reactive immunity to human Cytomegalovirus glycoprotein B.对人巨细胞病毒糖蛋白 B 的异亚型、交叉反应性免疫。
Clin Exp Immunol. 2022 Jun 11;208(2):245-254. doi: 10.1093/cei/uxac031.
8
A conditionally replication-defective cytomegalovirus vaccine elicits potent and diverse functional monoclonal antibodies in a phase I clinical trial.一种条件性复制缺陷型巨细胞病毒疫苗在一项I期临床试验中引发了强效且多样的功能性单克隆抗体。
NPJ Vaccines. 2021 Jun 2;6(1):79. doi: 10.1038/s41541-021-00342-3.
9
Rationally designed Human Cytomegalovirus gB nanoparticle vaccine with improved immunogenicity.具有增强免疫原性的合理设计的人巨细胞病毒gB纳米颗粒疫苗。
PLoS Pathog. 2020 Dec 28;16(12):e1009169. doi: 10.1371/journal.ppat.1009169. eCollection 2020 Dec.
10
Original Antigenic Sin Shapes the Immunological Repertoire Evoked by Human Cytomegalovirus Glycoprotein B/MF59 Vaccine in Seropositive Recipients.原始抗原决定簇决定了人巨细胞病毒糖蛋白 B/MF59 疫苗在血清阳性受者中引发的免疫反应谱。
J Infect Dis. 2019 Jun 19;220(2):228-232. doi: 10.1093/infdis/jiz089.
中和抗体可检测到人巨细胞病毒包膜内一种二硫键连接的糖蛋白复合物。
Virology. 1984 Jun;135(2):369-78. doi: 10.1016/0042-6822(84)90193-4.
4
Selection of particles and proteins for use as human cytomegalovirus subunit vaccines.用于人巨细胞病毒亚单位疫苗的颗粒和蛋白质的选择。
Birth Defects Orig Artic Ser. 1984;20(1):305-24.
5
Priming for and induction of anti-poliovirus neutralizing antibodies by synthetic peptides.合成肽引发和诱导抗脊髓灰质炎病毒中和抗体
Nature. 1983;304(5928):699-703. doi: 10.1038/304699a0.
6
Cytotoxic t cells in cytomegalovirus infection: HLA-restricted T-lymphocyte and non-T-lymphocyte cytotoxic responses correlate with recovery from cytomegalovirus infection in bone-marrow-transplant recipients.巨细胞病毒感染中的细胞毒性T细胞:骨髓移植受者中HLA限制性T淋巴细胞和非T淋巴细胞的细胞毒性反应与巨细胞病毒感染的恢复相关。
N Engl J Med. 1982 Jul 1;307(1):7-13. doi: 10.1056/NEJM198207013070102.
7
Prevention of transfusion-acquired cytomegalovirus infections in newborn infants.预防新生儿输血获得性巨细胞病毒感染。
J Pediatr. 1981 Feb;98(2):281-7. doi: 10.1016/s0022-3476(81)80662-2.
8
Cytomegalovirus disease in renal allograft recipients: a prospective study of the clinical features, risk factors and impact on renal transplantation.肾移植受者的巨细胞病毒病:一项关于临床特征、危险因素及对肾移植影响的前瞻性研究
Medicine (Baltimore). 1980 Jul;59(4):283-300.
9
Antibodies that react with predetermined sites on proteins.与蛋白质上预先确定位点发生反应的抗体。
Science. 1983 Feb 11;219(4585):660-6. doi: 10.1126/science.6186024.
10
Immunogenic structure of the influenza virus hemagglutinin.流感病毒血凝素的免疫原性结构。
Cell. 1982 Mar;28(3):477-87. doi: 10.1016/0092-8674(82)90202-1.